A Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202), Trial ID 7465-CL-202

试验摘要

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR).

This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin.

获取更多信息

关于正在招募参与者的 A Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)，您是否想了解更多临床试验中心相关信息？请在右侧填写您的信息联系我们，我们将予以回复。

询问者信息（我是……）

A caregiver
A healthcare provider
A parent
A patient
A patient advocate

名字

姓氏

电子邮箱

国家/地区

中国
中国台湾
中国香港
丹麦
乌克兰
亚美尼亚
以色列
俄罗斯联邦
保加利亚
克罗地亚
冰岛
前塞尔维亚和黑山
加拿大
匈牙利
南非
印度
印度尼西亚
危地马拉
哈萨克斯坦
哥伦比亚
土耳其
埃及
塞尔维亚
多米尼加共和国
奥地利
巴拿马
巴西
希腊
德国
意大利
拉脱维亚
挪威
捷克共和国
摩尔多瓦共和国
摩洛哥
斯洛伐克
斯洛文尼亚
新加坡
新西兰
日本
智利
格鲁吉亚
比利时
沙特阿拉伯
法国
波兰
波多黎各
波斯尼亚和黑塞哥维那
泰国
澳大利亚
爱尔兰
爱沙尼亚
瑞典
瑞士
白俄罗斯
秘鲁
立陶宛
约旦
罗马尼亚
美国
芬兰
英国
荷兰
菲律宾
葡萄牙
西班牙
越南
阿尔及利亚
阿根廷
韩国
马其顿共和国
马来西亚
黎巴嫩
黑山
墨西哥

点击“继续/提交”代表您同意安斯泰来通过电子邮件联系您，并向您提供信息帮助您与临床试验中心取得联系。我们可以向您提供临床试验中心的联系信息，但我们不能通过电子邮件回答任何关于研究性疗法的问题。您同意接受电子邮件不是参与临床试验或研究的要求。如需更多信息，包括如何随时取消订阅，请查看我们的。隐私声明和 Cookie 政策.

本人同意根据安斯泰来隐私声明和 Cookie 政策处理以上个人数据

地点

联系我们

正在招募

Site JP81002

Koto, Tokyo, 日本

联系我们

正在招募

Gettysburg Cancer Center

Gettysburg, PA, 美国, 17375

联系我们

正在招募

Seattle Cancer Care Alliance

Seattle, WA, 美国, 98109

联系我们

正在招募

Site JP81004

Nagoya, Aichi, 日本

联系我们

正在招募

Site JP81003

Chuo, Tokyo, 日本

联系我们

正在招募

New York University Langone Health

New York, NY, 美国, 10016

联系我们

正在招募

Piedmont Hospital

Atlanta, GA, 美国, 30318

联系我们

正在招募

Site JP81001

Kashiwa, Chiba, 日本

联系我们

Active, not recruiting

Mary Crowley Research Center

Dallas, TX, 美国, 75230

联系我们

正在招募

Arizona Oncology

Tucson, AZ, 美国, 85711

联系我们

正在招募

University of Kansas

Fairway, KS, 美国, 66205

联系我们

正在招募

Site JP81006

Nagaizumi, Shizuoka, 日本

联系我们

正在招募

University of Colorado

Aurora, CO, 美国, 80045

联系我们

正在招募

Comprehensive Cancer Centers of Nevada

Las Vegas, NV, 美国, 89169

联系我们

正在招募

Indiana University Cancer Center

Indianapolis, IN, 美国, 46202

联系我们

Withdrawn

University of Southern California

Los Angeles, CA, 美国, 90033

联系我们

Withdrawn

Washington University in St. Louis

St. Louis, Mo, 美国, 63110

联系我们

正在招募

University of Michigan

Ann Arbor, MI, 美国, 48109

联系我们

正在招募

Florida Cancer Specialists

Tallahassee, FL, 美国, 32308

联系我们

正在招募

Northside Hospital

Atlanta, GA, 美国, 30342

联系我们

正在招募

Northwestern University Medical Center

Chicago, IL, 美国, 60611

联系我们

正在招募

Ohio State University

Columbus, OH, 美国, 43210

联系我们

正在招募

Cleveland Clinic

Cleveland, OH, 美国, 44195

联系我们

正在招募

Nebraska Methodist Hospital

Omaha, NE, 美国, 68114

联系我们

正在招募

Wisconsin Carbone Cancer Center

Madison, WI, 美国, 53792

联系我们

正在招募

Florida Cancer Specialists

West Palm Beach, FL, 美国, 33401

联系我们

正在招募

Florida Cancer Specialists

Fort Myers, FL, 美国, 33901

联系我们

正在招募

Site JP81005

Chuo-ku, Osaka, 日本

联系我们

正在招募

Henry Ford Hospital

Detroit, MI, 美国, 48202

联系我们

正在招募

Rutgers Cancer Institute

New Brunswick, New Jersey, 美国, 08901

联系我们

正在招募

University of Chicago

Chicago, IL, 美国, 60637

联系我们

正在招募

Dana-Farber Cancer Institute

Boston, MA, 美国, 02215

联系我们

正在招募

University of Texas

Houston, TX, 美国, 77030

联系我们

正在招募

Ochsner Medical Center

New Orleans, LA, 美国, 70121

联系我们

正在招募

Site CA15001

Hamilton, ON, 加拿大, L8V 5C2

联系我们

正在招募

Site CA15003

Ottawa, ON, 加拿大, K1H 8L6

联系我们

正在招募

University of Minnesota Cancer Center

Minneapolis, MN, 美国, 55455

联系我们

正在招募

Dartmouth-Hitchcock Norris Cotton Cancer Center

黎巴嫩, NH, 美国, 03765

联系我们

正在招募

Sarah Cannon Research Institute

Nashville, TN, 美国, 37203

联系我们

正在招募

University of Cincinnati

Cincinnati, OH, 美国, 45219

联系我们

正在招募

Site JP81007

Osaka-Sayama, Osaka, 日本

联系我们

正在招募

Memorial Sloan Kettering Cancer Center

New York, NY, 美国, 10022

联系我们

正在招募

Site CA15002

Vancouver, BC, 加拿大, V5Z 4E6

联系我们

正在招募

Providence St. Joseph Medical Center

Burbank, CA, 美国, 91505

联系我们

正在招募

Site JP81009

Shinjuku-ku, Tokyo, 日本

联系我们

正在招募

Site JP81010

Okayama, Okayama, 日本

联系我们

正在招募

Site JP81011

Kitaadachi-Gun, Saitama, 日本

联系我们

正在招募

University of Nebraska

Omaha, NE, 美国, 68105

联系我们

正在招募

Site CA15005

Montreal, Quebec, 加拿大, H3T 1E2

联系我们

正在招募

University of California - San Francisco

San Francisco, CA, 美国, 94158

联系我们

正在招募

Beth Israel Deaconess Medical Center

Boston, MA, 美国, 02215

联系我们

试验信息

关注试验

参与者年龄

18 岁及以上

疾病

晚期/转移性肿瘤

参与者性别

女性和男性

试验开展时间

Mar 2020 - Apr 2024

分享给

更多研究详情

入选标准

Subject is considered an adult according to local regulation at the time of signing the informed consent form (ICF).
Subject has measurable disease by RECIST Version 1.1.
Subject has accessible archival tumor tissue from either the primary tumor or a metastatic site, for which source and availability have been confirmed prior to study treatment. If no archival tumor tissue is available, the subject will have a biopsy to obtain tumor tissue prior to study treatment. If the subject is unable to undergo a biopsy due to safety concerns, enrollment into the study must be discussed with the medical monitor.
Subject has ECOG performance status of 0 or 1.
Subject has the following baseline laboratory data. If a subject has received a recent blood transfusion, the hematology tests must be obtained ≥ 28 days after any blood transfusion.
- 中性粒细胞绝对计数（ANC）≥ 1.0 × 10^9/L
- 血小板计数 ≥ 100 × 10^9/L
- 血红蛋白 ≥ 9 g/dL
- serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for subjects with Gilbert’s disease
- 根据机构标准估算或通过 24 小时尿液采集测得的肌酐清除率（CrCl）≥ 30 mL/min（也可以使用肾小球滤过率[GFR]代替 CrCl）
- 丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）≤ 3 倍 ULN
Subject agrees not to participate in another interventional study while receiving study treatment in the present study.
Additional contraceptive requirements exist for male and female subjects.

Disease Specific Inclusion Criteria:

Evidence of progression on or after the last regimen received.
Locally advanced or metastatic disease that is not amenable to curative intent treatment.

Cohort 1: HR+/HER2- breast cancer

Subject has evidence of radiographic progression on or after the last regimen received.
Subject has histologically- or cytologically-confirmed HR+/HER2- (estrogen receptor [ER] positive and/or progesterone receptor [PR] positive, and HER2 negative) breast cancers and are not considered a candidate for further hormonal therapy. Subject will be considered HR+ if biopsies show ≥ 1% expression of ER or PR as per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.
- Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.
Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received > 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. No limit applies to endocrine therapies. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.
Subject has progressed, relapsed, or discontinued for toxicity during or after receiving endocrine therapy or with hormonally-directed therapy with cyclin-dependent kinase (CDK) inhibitors. Prior therapy with CDK inhibitors is not required.

Cohort 2: triple negative breast cancer (TNBC)

Subject has evidence of radiographic progression on or after the last regimen received.
Subject has histologically- or cytologically-confirmed TNBC; defined as unequivocal TNBC histology (ER-negative/PR-negative/HER2-negative). This is defined by < 1% expression of ER and PR by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified) as per current ASCO/CAP guidelines.
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.
- Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.
Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received > 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.
Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) based on subject’s tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohort 3: squamous non-small cell lung cancer (NSCLC)

Subject has evidence of radiographic progression on or after the last regimen received.
Subject has histologically or cytologically-confirmed squamous NSCLC.
- Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.
- Subjects with known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.

(a.) Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.

(b.) Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.

(c.) Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression had occurred while on the initial therapy.

Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or anti-programmed cell death-ligand 1 (PD-L1) based on subject’s tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohort 4: non-squamous non-small cell lung cancer

Subject has evidence of radiographic progression on or after the last regimen received.
Subject has histologically- or cytologically-confirmed non-squamous NSCLC.
- Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.
- Subjects with known EGFR, ALK, ROS, BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.

(b.) Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.

Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject’s tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohort 5: head and neck cancer

Subject has evidence of radiographic progression on or after the last regimen received.
Subject has histologically- or cytologically-confirmed head and neck cancer.
- Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 5.
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.
- Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months after completion.
Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject’s tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

Cohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal adenocarcinoma

Subject has evidence of radiographic progression on or after the last regimen received.
Subject has histologically- or cytologically-confirmed gastric, GEJ, or esophageal cancer.
Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.
Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.
- Neoadjuvant or adjuvant cytotoxic regimens will count as a prior regimen if relapsed or progressed ≤ 6 months after completion.
Subject must have received a HER2 directed therapy if known to have HER2 positive cancer.
Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject’s tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.

排除标准

Subject has preexisting sensory or motor neuropathy Grade ≥ 2.
Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:
- CNS metastases have been clinically stable for ≥ 6 weeks prior to screening
- If requiring steroid treatment for CNS metastases, the subject is on a stable dose ≤ 20 mg/day of prednisone or equivalent for ≥ 2 weeks
- Baseline imaging scans show no evidence of new or enlarged brain metastasis
- Subject does not have leptomeningeal disease
Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).
Subjects with ongoing ≥ Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (> 20 mg/day of prednisone or equivalent), are excluded. Subject with ≤ Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated).
Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) ≥ 8% or HbA1c between 7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.
Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).
Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. 允许接受常规抗菌预防。- Subject has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or active hepatitis C (e.g., hepatitis C virus [HCV] RNA [qualitative] is detected).
Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).
Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.
Subject has major surgery within 4 weeks prior to first dose of study drug.
Subject had radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.
Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.
Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.
Subject has any condition which makes the subject unsuitable for study participation.

常见问题

临床试验是否只针对晚期癌症患者？

虽然某些临床试验可能侧重于更晚期的癌症，但许多试验对处于不同癌症阶段的患者开放。每项研究都有关于参与资格的规定。例如，只有特定年龄段的患者或患有特定类型肿瘤的患者才能参与。

我是否需要停止当前治疗才能参加临床试验？

有时，研究人员希望参与者在临床试验期间继续接受当前治疗。有时，您可能需要暂停当前的治疗。如果研究性治疗无效，您通常可以恢复原有的治疗方案。

我是否应该担心会服用安慰剂？

在癌症临床试验中，只有当该类癌症尚无其他治疗方法时，才会使用安慰剂。这有助于将研究性治疗与安慰剂进行比较。安慰剂在癌症试验中很少使用，因为通常会采用最佳可用疗法，即所谓的“标准治疗方案”。

我是否需要医生转诊才能参加一项研究？

您的医生可能并不了解所有可供您参与的临床试验机会。请与您的医生或其他医疗服务提供者讨论您所找到的临床试验信息。他们可以帮助您判断临床试验是否适合您。若您在本网站未找到任何试验选择，我们建议您访问在线公共注册网站，例如 ClinicalTrials.gov 查看各种可参与的临床试验。

探索更多

A Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

试验摘要

更多研究详情

获取更多信息

地点

常见问题

探索更多

什么是临床试验?

为什么临床试验很重要？

为什么要参加临床试验